-
Clinical depression is highly prevalent in the general population and in primary care settings. Although clinicians presently have a broad array of pharmacological agents for the treatment of depression, including selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors, overall response rates and remission rates with these pharmacological agents remain relatively modest.
-
The increasing sophistication of molecular tools is allowing for the discovery of all kinds of novel strains of bacteria; witness the multiple new strains of Rickettsia discovered around the world.
-
CDI can be a difficult-to-manage complication of antibiotic therapy. Although it is preferable to discontinue the inciting antibiotic when CDI occurs, this is not always possible given that many patients have serious infections, which require ongoing antibiotic therapy.
-
-
Two human cystic fibrosis (CF) bronchial epithelial cell lines and one CF human primary epithelial cell line in culture were treated with AZM at 10 µg/mL.
-
A retrospective review of pediatric malaria at a Washington, DC, children's hospital identified 98 cases over 8 years (1999-2006). Their mean age was 9.6 years.
-
-
Oude Lashof and colleagues examined the incidence and outcomes of patients with ocular involvement in a randomized, clinical trial comparing treatment of non-neutropenic patients with candidemia with either voriconazole or amphotericin B followed by fluconazole.
-
A 58-year-old Liberian-born woman was in excellent general health, living and working in a large academic medical center in Rhode Island for more than 20 years, when she developed nonspecific gastrointestinal symptoms and underwent endoscopy, which revealed Strongyloides stercoralis larvae on a duodenal biopsy in March 2010.
-
In this issue: Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.
